SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2022 on Thursday, January 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
Earnings webcast details:
• | Location: | http://investor.resmed.com |
• | Date: | Thursday, January 27, 2022 |
• | Time: | 1:30 p.m. PST / 4:30 p.m. EST |
• | International: | London, Thursday, January 27, 9:30 p.m. GMT |
Sydney, Friday, January 28, 8:30 a.m. AEDT |
Please note that ResMed does not use outside phone lines to access the earnings call.
A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from January 27 until February 10 at:
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
For investors | For media |
Amy Wakeham | Jayme Rubenstein |
+1 858.836.5000 | +1 858.836.6798 |
investorrelations@resmed.com | news@resmed.com |
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…